The present invention is directed to a compound of Formula (I)
##STR00001## wherein Cy.sup.1, Cy.sup.2, L.sup.1, L.sup.2, and R.sup.1
are as defined herein, a pharmaceutical composition comprising a
pharmaceutically effective amount of one or more compounds according to
Formula (I) in admixture with a pharmaceutically acceptable carrier, and
a method of treating a patient suffering from a PGD2-mediated disorder
including, but not limited to, allergic disease (such as allergic
rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma
and food allergy), systemic mastocytosis, disorders accompanied by
systemic mast cell activation, anaphylaxis shock, bronchoconstriction,
bronchitis, urticaria, eczema, diseases accompanied by itch (such as
atopic dermatitis and urticaria), diseases (such as cataract, retinal
detachment, inflammation, infection and sleeping disorders) which is
generated secondarily as a result of behavior accompanied by itch (such
as scratching and beating), inflammation, chronic obstructive pulmonary
diseases, ischemic reperfusion injury, cerebrovascular accident, chronic
rheumatoid arthritis, pleurisy, ulcerative colitis and the like by
administering to said patient a pharmaceutically effective amount of a
compound according to Formula (I).